In Reply
letter
OA: closed
CC0
AI-generated summary
This document details financial disclosures for Dr. Simon regarding consulting, advisory, speaker bureau, and stock ownership roles with various pharmaceutical and biotechnology companies.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
George Washington University School of Medicine, Women's Health & Research Consultants, Washington, DC Financial Disclosure Dr. Simon has served as a consultant/advisor to AbbVie, Allergan, AMAG Pharmaceuticals, ASCEND Therapeutics, Azure Biotech, Millendo Therapeutics, Nuelle, Radius Health, Regeneron Pharmaceuticals, Roivant Sciences, Sanofi, Sebela Pharmaceuticals, Sermonix Pharmaceuticals, Shionogi, Symbiotec Pharmalab, TherapeuticsMD, and Valeant Pharmaceuticals; has served on speaker bureaus of Novo Nordisk, Shionogi, and Valeant Pharmaceuticals; has received grant/research support from AbbVie, Allergan, Agile Therapeutics, Bayer HealthCare, New England Research Institute, ObsEva, Palatin Technologies, Symbio Research, and TherapeuticsMD; and is a stockholder (direct purchase) in Sermonix Pharmaceuticals. The author thanks Complete HealthVizion for editorial support.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (1)
- W2789792078 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK